Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Rating) have been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $46.13.

A number of brokerages recently weighed in on XNCR. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Tuesday, February 28th. EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $42.00 target price on shares of Xencor in a research report on Friday, February 24th. Royal Bank of Canada decreased their target price on Xencor from $40.00 to $36.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 8th. JPMorgan Chase & Co. upped their price objective on Xencor from $37.00 to $42.00 and gave the company an “overweight” rating in a research report on Monday, February 13th. Finally, SVB Leerink restated an “outperform” rating on shares of Xencor in a research report on Thursday, February 23rd.

Xencor Trading Up 1.6 %

Shares of NASDAQ XNCR opened at $31.93 on Monday. Xencor has a twelve month low of $19.35 and a twelve month high of $38.20. The stock has a 50 day moving average of $31.17 and a two-hundred day moving average of $28.97. The stock has a market cap of $1.92 billion, a P/E ratio of -34.33 and a beta of 0.82.

Xencor (NASDAQ:XNCR – Get Rating) last issued its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.63. The company had revenue of $21.61 million during the quarter, compared to analysts’ expectations of $19.24 million. Xencor had a negative return on equity of 7.47% and a negative net margin of 33.53%. The firm’s revenue for the quarter was down 86.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 earnings per share. As a group, research analysts predict that Xencor will post -2.86 earnings per share for the current year.

Insider Activity

In other news, CMO Allen Yang sold 3,737 shares of the stock in a transaction dated Monday, December 19th. The stock was sold at an average price of $27.00, for a total value of $100,899.00. Following the completion of the sale, the chief marketing officer now owns 63,521 shares in the company, valued at $1,715,067. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund grew its stake in shares of Xencor by 1.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,934 shares of the biopharmaceutical company’s stock worth $519,000 after purchasing an additional 325 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Xencor by 3.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,418 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 333 shares during the period. State of Alaska Department of Revenue boosted its stake in Xencor by 1.0% during the fourth quarter. State of Alaska Department of Revenue now owns 41,726 shares of the biopharmaceutical company’s stock valued at $1,086,000 after buying an additional 395 shares in the last quarter. Quadrant Capital Group LLC raised its position in Xencor by 19.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,606 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 426 shares in the last quarter. Finally, EP Wealth Advisors LLC boosted its position in shares of Xencor by 3.5% during the 2nd quarter. EP Wealth Advisors LLC now owns 13,553 shares of the biopharmaceutical company’s stock valued at $371,000 after purchasing an additional 463 shares in the last quarter. Institutional investors and hedge funds own 98.99% of the company’s stock.

About Xencor

(Get Rating)

Xencor, Inc is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.